Status:
COMPLETED
Sugammadex Titration in Cardiac Surgery Patients
Lead Sponsor:
University of Washington
Conditions:
Coronary Artery Disease
Valvular Heart Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Sugammadex is frequently used to reverse the effects of neuromuscular blocking drugs. The recommended doses are 2 mg/kg or 4 mg/kg depending upon the depth of neuromuscular blockade. Clinical studies ...
Detailed Description
Neuromuscular blocking drugs are used frequently during general anesthesia. The effects of neuromuscular blocking drugs are measured using a twitch monitor, that stimulates the ulnar nerve and measure...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- All cardiac surgery patients
- Exclusion Criteria:
- Allergic or other adverse response to sugammadex
Exclusion
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 10 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05246397
Start Date
February 1 2022
End Date
November 10 2022
Last Update
March 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Washington Medical Center
Seattle, Washington, United States, 98195